Ligand enters financing deal with AvenCell Therapeutics for up to $47 million
Bitget2026/09/24 11:02- Ligand Pharmaceuticals entered a financing agreement with AvenCell Therapeutics to fund next-generation allogeneic CAR-T programs for up to $47 million.
- Commitment includes up to $41 million for a mid single-digit to low double-digit royalty on worldwide net sales across AvenCell’s pipeline.
- Funding will be paid in four tranches, with later payments tied to clinical milestones and specified financing conditions.
- Ligand also committed up to $6 million in a concomitant Series C financing.
- Proceeds target development of AVC-201 in a Phase 1b AML expansion study, with AVC-203 in Phase 1a for B-cell malignancies.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
